Dealmaking is back, and that’s good news for Wall Street in more ways than one.
Total M&A activity is running at record levels, with $US4.7 trillion in activity in the year to date, according to Credit Suisse. There’s been $US2.4 trillion of deals in the US alone, up from $US1.6 trillion in the same period in 2007, the previous peak.
For investment banks, the surge in deals can have a multiplier effect — with the revenues they generate extending far beyond straight-up advisory fees.
Once a bank is involved in a deal, it can earn fees from bond and equity sales to finance the takeover. Consider the drugmakers Teva and Allergan. Freeman & Co. estimates they have paid more than $US800 million in fees between for advice on purchases, sales, and fundraising for deals since 2012.
This revenue stream can continue long after a deal is done, Barclays analysts note.
“There is the potential for additional advisory fees to the further rationalize acquired firms, as well as meeting possible divesture requirements,” they wrote in a note Thursday.
And that is why Wall Street’s dealmakers — who were laying low in the years after the financial crisis — are back in the ascendancy.
Business Insider Emails & Alerts
Site highlights each day to your inbox.